AtriCure - ATRC Stock Forecast, Price & News

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

AtriCure Price Performance

ATRC Stock traded up $1.88 during midday trading on Wednesday, reaching $50.80. The company had a trading volume of 155,224 shares, compared to its average volume of 267,413. The company has a market capitalization of $2.36 billion, a price-to-earnings ratio of 43.79 and a beta of 1.20. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.66 and a quick ratio of 2.93. AtriCure has a 1-year low of $32.83 and a 1-year high of $89.18. The stock has a 50 day moving average price of $43.09 and a 200-day moving average price of $52.97.

AtriCure (NASDAQ:ATRC - Get Rating) last announced its quarterly earnings data on Tuesday, August 2nd. The medical device company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.02). AtriCure had a net margin of 17.62% and a negative return on equity of 11.47%. During the same quarter in the prior year, the firm earned ($0.30) earnings per share. Equities research analysts expect that AtriCure will post -1.09 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ATRC. Stifel Nicolaus reduced their price objective on AtriCure from $70.00 to $50.00 in a report on Monday, July 18th. Needham & Company LLC increased their price objective on AtriCure from $55.00 to $65.00 and gave the stock a "buy" rating in a research report on Wednesday, August 3rd. BTIG Research reduced their target price on shares of AtriCure from $94.00 to $75.00 and set a "buy" rating for the company in a research report on Friday, June 24th. Piper Sandler decreased their price target on shares of AtriCure from $90.00 to $55.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 3rd. Finally, StockNews.com cut shares of AtriCure from a "hold" rating to a "sell" rating in a research note on Sunday. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $75.86.

Insider Transactions at AtriCure

In other AtriCure news, insider Tonya Austin sold 3,203 shares of AtriCure stock in a transaction dated Friday, May 13th. The stock was sold at an average price of $42.69, for a total value of $136,736.07. Following the transaction, the insider now owns 17,621 shares in the company, valued at $752,240.49. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.80% of the stock is owned by insiders.